Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

https://www.theros1ders.org/post/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-non-small-cell-lung

• Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 • Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC • GSK